期刊文献+

生物免疫治疗在胰腺癌中的现状及展望 被引量:1

The current status and perspectives of immunotherapy in pancreatic adenocarcinomas
原文传递
导出
摘要 胰腺癌是恶性程度最高的消化系统恶性肿瘤之一,其手术切除率低、早期即可转移,且胰腺癌对放化疗均不敏感,目前治疗效果不满意。寻找有效的治疗方式是目前胰腺癌治疗亟待解决的问题。近10余年来胰腺癌基础研究促进了免疫治疗在胰腺癌中的应用,同时胰腺癌免疫治疗的一些前期临床实验也取得了一些鼓舞人心的结果。本文将就胰腺癌免疫治疗在近年来所取得的一些成果及应用现状、前景作一综述。 Pancreatic adenocarcinoma is one of the most highly malignant digestive system cancers, and current therapeutic strategies are often unsatisfactory. It is associated with a high mortality rate because of low resection rate, early metastasis, and poor ehemoradiotherapy response. Identification and development of more efficacious therapies is urgently needed. The basic research promoted the development of immunotherapy for pancreatic cancer, and immunotherapy offered encouraging results in some preclinical trials during the last decade. The aim of this review is to summarize the recent advances in immunotherapy and to evaluate the future perspectives of immunotherapy in the treatment of pancreatic adenocarcinoma.
作者 王俊 李升平
出处 《中国医师杂志》 CAS 2015年第12期1790-1793,共4页 Journal of Chinese Physician
关键词 胰腺肿瘤/治疗 免疫疗法 综述 Pancreatic neoplasms/TH Immunotherapy Review
  • 相关文献

参考文献32

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014 [ J]. CA Cancer J Clin,2014,64( 1 ) :9-29.
  • 2苑喜明,张彩清.同步放化疗治疗局部晚期胰腺癌的疗效观察[J].中国医师杂志,2015,17(7):1062-1063. 被引量:6
  • 3Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age[J]. Nature, 2011,480(7378) :480-489.
  • 4Emens LA. GM-CSF-secreting vaccines for solid tumors [ J ]. Curr Opin Investig Drugs, 2009,10(12) : 1315-1324.
  • 5Jaffee Em, Hruban RH, Biedrzycki B, et al. Novel allogeneic granu- locyte-macrophage colony-stimulating factor-secreting tumor wa- ceine for pancreatic cancer: a phase I trial of safety and immune activation[ J]. J Clin Onco1,2001,19 ( 1 ) :145-156.
  • 6Lutz E, Yeo C J, Lillemoe KD, et al. A lethally irradiated alloge- neic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocareinoma. A Phase II trial of safety, efficacy, and immune activation [ J ]. Ann Surg,2011, 253 (2) : 328-335.
  • 7Nakamura M, Wada J, Suzuki H, et al. Long-term outcome of im- munotherapy for patients with refractory pancreatic cancer [ J ]. Anticancer Res, 2009, 29 (3) : 831-836.
  • 8孙诚谊,孙早喜,王福生.DC疫苗诱导免疫效应细胞对BEL7 402和PC3的生长抑制[J].中华肝胆外科杂志,2006,12(5):343-345. 被引量:2
  • 9杨德红,刘文佳,陈敏,吴育美,邹晓平.经卡介苗活化的负载PANC1裂解产物的树突状细胞疫苗体外抗胰腺癌作用[J].中华胰腺病杂志,2010,10(4):267-271. 被引量:3
  • 10Dudek NL, Perlmutter P, Aguilar MI, et al. Epitope discovery and their use in peptide based vaccines [ J ]. Curr Pharm Des, 2010,16(28) :3149-3157.

二级参考文献31

  • 1吴雨岗,汪良,张雁云.人外周血树突状细胞的体外扩增、鉴定及内吞能力的测定[J].中国血液流变学杂志,2004,14(4):444-447. 被引量:6
  • 2Gunzer M, Janich S, Varga G, et al. Dendritic celle and tumor immunity. Semin Immunol, 2001,13 : 291-302.
  • 3Zhang M, Wang Q, Liu Y, et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med ,2004,82:240-249.
  • 4Kim KD,Lee HG,Kim JK, et al. Enhanced antigen-presenting activity and turnout necrosis factor alpha independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guerin. Immunology, 1999,97:626-33.
  • 5Chen B,Shi Y,Smith JD, et al. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4^+ T cells in vitro. Blood, 1998,91:4652-4661.
  • 6Um HD, Cho YH, Kim DK, et al. TNF-alpha suppresses dendritic cell death and the production of reactive oxygen intermediates induced by plasma withdrawal. Exp Dermatol, 2004, 13: 282- 288.
  • 7Stockinger B,Bourgenois C, Kassiotis G. CD4^+ memory T cells: functional differentiation and homeostasis, hnmunol Rev, 2006, 211:39-48.
  • 8Onoe K, Yanagawa Y, Minam K, et al. Th1 or Th2 balance regulated by interation between dendritic cells and NKT cells. Immunol Res ,2007,38:319-332.
  • 9Trinehieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol, 1995, 13:251-276.
  • 10Ferlazzo G,Pack M,Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA,2004, 101 : 16608-16611.

共引文献8

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部